Kymera Therapeutics KYMR Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's finance lease liabilities?
- Kymera Therapeutics (KYMR) reported finance lease liabilities of $1.15M in Q1 2026.
- How has Kymera Therapeutics's finance lease liabilities changed year-over-year?
- Kymera Therapeutics's finance lease liabilities decreased by 39.7% year-over-year, from $1.91M to $1.15M.
- What is the long-term trend for Kymera Therapeutics's finance lease liabilities?
- Over 5 years (2020 to 2025), Kymera Therapeutics's finance lease liabilities has grown at a 19.3% compound annual growth rate (CAGR), from $604K to $1.46M.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.